What Arvinas does

Arvinas is a clinical-stage biotechnology company headquartered in New Haven, Connecticut, founded in 2013 to commercialize targeted protein degradation therapeutics based on research by Dr. Craig Crews at Yale University. The company's core technology is its proprietary PROTAC (PROteolysis TArgeting Chimeras) Discovery Engine, which designs heterobifunctional small-molecule degraders that harness the body's ubiquitin-proteasome system to selectively eliminate disease-causing proteins - including the ~80% of the proteome considered 'undruggable' by traditional small-molecule inhibitors. The platform incorporates an E3 KnowledgeBase covering more than 600 E3 ligases, DNA-Encoded Library screening, and proprietary linker chemistry (ANGLE), and has produced orally bioavailable candidates capable of penetrating the blood-brain barrier.

The product portfolio spans oncology and neurology. On May 1, 2026, the FDA approved VEPPANU (vepdegestrant) for ER+/HER2-/ESR1-mutated advanced breast cancer - the first-ever approved PROTAC protein degrader - alongside a companion diagnostic (Guardant360 CDx). Clinical-stage assets include ARV-102 (LRRK2 for Parkinson's disease and PSP), ARV-027 (polyQ-AR for SBMA), ARV-393 (BCL6 for non-Hodgkin lymphoma), ARV-806 (KRAS G12D for solid tumors), ARV-6723 (HPK1 for immuno-oncology), and luxdegalutamide (ARV-766) for prostate cancer.

Arvinas monetizes primarily through licensing and collaboration rather than direct commercialization. Revenue streams include upfront payments, development/regulatory/commercial milestones, and tiered royalties on net sales of partner-led products. Major deals include a $150M upfront plus up to $1.01B milestones from Novartis for luxdegalutamide (April 2024), and a $70M upfront plus up to $320M milestones from Rigel for VEPPANU (May 2026), with Rigel handling global commercialization and targeting an August 2026 launch. FY2025 revenue was $262.6M and Q1 2026 revenue was $15.6M; cash and marketable securities of $614.9M (Q1 2026) are stated to fund operations into the second half of 2028.

Name

Arvinas

Legal name

Arvinas Operations, Inc.

Website

https://arvinas.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

251–500 employees

Short description

Arvinas is a clinical-stage biotechnology company that develops PROTAC protein degrader therapeutics using its proprietary targeted protein degradation platform, advancing one FDA-approved breast cancer therapy and multiple clinical-stage oncology and neurology programs, monetized primarily through licensing partnerships with Pfizer, Novartis, and Rigel.

Ownership category

akta.pro rank

Product category

Targeted Protein Degradation Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industry

Therapeutic Enzymes & Enzyme Replacement Therapies (ERT) (HLAAAAAK)

Keywords

• Targeted protein degradation
• PROTAC therapeutics
• Oncology drug development
• Biopharmaceutical research
• Protein degrader platform

Headquarters

HQ city

New Haven

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Licensing and Milestone Payments: Arvinas generates revenue through upfront payments, development milestones, regulatory milestones, and commercial milestones from licensing agreements with pharmaceutical partners. Examples include $150 million upfront from Novartis for luxdegalutamide and $70 million upfront from Rigel for VEPPANU, plus up to $320 million in potential milestones.
2. Royalty Income: Arvinas receives tiered royalties on net sales of commercialized products licensed to partners. VEPPANU licensing includes tiered royalties on net sales. Luxdegalutamide licensing includes tiered royalties based upon worldwide net sales.
3. Collaboration Revenue: Revenue from ongoing collaboration activities with pharmaceutical partners including Pfizer for vepdegestrant development. Revenue fluctuates based on development activities and cost sharing arrangements.
4. Private Placement Financing: Arvinas has raised significant equity capital through private placements. In November 2023, the company secured $350 million through a private placement of common stock and pre-funded warrants to institutional investors including EcoR1 Capital and RTW Investments.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Arvinas is a clinical-stage biotechnology company that develops PROTAC (PROteolysis TArgeting Chimera) protein degraders—heterobifunctional small molecules that harness the body's ubiquitin-proteasome system to selectively degrade disease-causing proteins. The company has one FDA-approved product (VEPPANU/vepdegestrant for ER+/HER2-/ESR1-mutated breast cancer) and a pipeline of clinical-stage PROTAC candidates across oncology and neuroscience, which it advances through clinical development and then out-licenses to large pharmaceutical partners for commercialization.

Product overview

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapeutics based on its proprietary PROTAC (PROteolysis TArgeting Chimera) platform. The company has one FDA-approved product (VEPPANU for breast cancer), multiple clinical-stage programs (ARV-102 for neurological diseases, ARV-027 for SBMA, ARV-393 for lymphoma, ARV-806 for KRAS G12D cancers, ARV-6723 for solid tumors), and a licensed prostate cancer program (luxdegalutamide). The PROTAC Discovery Engine enables development of degraders that can target previously 'undruggable' proteins by leveraging the cell's natural ubiquitin-proteasome system.

Differentiator

Problem solved

Functional benefit

Brands

• VEPPANU: FDA-approved PROTAC therapy for ER+/HER2- breast cancer with ESR1 mutations
• PROTAC Discovery Engine

Products and services

• VEPPANU (vepdegestrant) First FDA-approved PROTAC protein degrader therapy, indicated for adults with ER+/HER2-/ESR1-mutated advanced or metastatic breast cancer following disease progression after at least one line of endocrine therapy. Works by selectively degrading the estrogen receptor protein in patients whose cancers are driven by ESR1 mutations. Licensed to Rigel Pharmaceuticals for global development, manufacturing, and commercialization; commercial launch expected August 2026.
• ARV-102 (LRRK2 degrader)

Quantifiable outcome

• VEPPANU demonstrated 43% reduction in disease progression risk versus fulvestrant in ESR1m population (VERITAC-2 Phase 3 trial)
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Six partnerships are on record, tiered supporting, core and minor.

• The Michael J. Fox FoundationsupportingStrategic or Co-development Partner · 4 June 2026Arvinas joined The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson's Precision Medicine Initiative (PPMI) to support advancement of ARV-102, its investigational PROTAC drug targeting LRRK2 for neurodegenerative diseases. The programs provide Arvinas access to collaborative research infrastructure, preclinical and translational resources, and open-access datasets to inform clinical strategy.
• Guardant HealthsupportingTechnology or Integration · 4 May 2026Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). The blood-based test enables non-invasive identification of patients with ESR1 mutations eligible for the targeted PROTAC therapy. The test is covered by Medicare and commercial payers representing more than 300 million covered lives.
• Rigel PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 May 2026In May 2026, Arvinas and Pfizer entered into a license agreement with Rigel Pharmaceuticals for the exclusive global development, manufacturing, and commercialization rights for VEPPANU (vepdegestrant). Arvinas and Pfizer received $85 million in upfront and transition payments ($70 million upfront plus $15 million development transition costs) and are eligible to receive up to $320 million in development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales. Rigel expects to commercially launch VEPPANU in August 2026.
• Novartis AGcoreChannel Partner/ Reseller/ Distributor · 1 April 2024In April 2024, Arvinas entered into a global license agreement with Novartis for the development and commercialization of luxdegalutamide (ARV-766, also known as JSB462) for the treatment of prostate cancer. The deal also included the sale of the AR-V7 program to Novartis. Arvinas received a one-time upfront payment of $150 million and is eligible to receive up to $1.01 billion in additional milestone payments plus tiered royalties on worldwide net sales.
• Pfizer Inc.coreStrategic or Co-development Partner · 1 January 2018In January 2018, Arvinas announced a research and collaboration license agreement with Pfizer for the discovery and development of drug candidates using Arvinas' PROTAC Discovery Engine. In July 2021, Arvinas and Pfizer expanded collaboration to globally develop and commercialize vepdegestrant. Following FDA approval of VEPPANU in May 2026, the companies licensed commercialization rights to Rigel while retaining sublicensing revenue rights outside the U.S.
• Genentech (Roche Group)minorStrategic or Co-development Partner · 1 October 2015In October 2015, Arvinas formed a strategic license agreement with Genentech to develop new therapeutics using Arvinas' PROTAC Discovery Engine. The collaboration was expanded in November 2017 to encompass additional disease targets. One target remains under the Genentech agreement.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Novartis: Global pharma that licensed Arvinas' luxdegalutamide for $150M upfront + up to $1.01B milestones. Comparable as a major oncology-focused pharmaceutical incumbent with internal degrader efforts (e.g., viaを買収 Dunad) and active PROTAC interest.
• Pfizer: Global pharmaceutical incumbent that is Arvinas' longest-standing strategic partner since 2018 and co-developer of vepdegestrant. Comparable as a broad oncology and protein-degradation-adjacent player, though at vastly larger scale and across many modalities.
• Bristol Myers Squibb: Large pharma with active targeted protein degradation and CELMoD (cereblon-based degrader) programs through its acquired Celgene franchise. Comparable as a major degrader-medicine developer and former employer of several Arvinas executives.

Direct peers

• Kymera Therapeutics: Clinical-stage biotech developing heterobifunctional small molecule protein degraders using its Pegasus platform against immunology and oncology targets (IRAK4, STAT6). Directly comparable to Arvinas as a fellow pure-play targeted protein degrader pursuing similar oncology and immunology indications.
• Nurix Therapeutics: Clinical-stage targeted protein degrader company with a broad pipeline (BTK degrader NX-2127, STAT6, etc.) and strategic collaborations with Gilead, Sanofi, and Pfizer. Highly comparable platform and business model to Arvinas, including partnership-driven revenue.
• Foghorn Therapeutics: Clinical-stage biotech developing therapeutics against chromatin regulatory proteins, including protein degrader approaches. Comparable platform-stage biotech with oncology focus and similar capital intensity profile.
• Monte Rosa Therapeutics: Clinical-stage developer of molecular glue degraders (MGDs) leveraging cereblon- and VHL-based approaches against oncology and immunology targets including GSPT1, NEK7, and BCL11A. Closely comparable to Arvinas' PROTAC protein degradation modality and similar pipeline stage.
• C4 Therapeutics: Clinical-stage biotech developing small molecule degraders (TORPEDO platform) against oncology targets including BCL6 and IKZF1/3. Direct competitor to Arvinas in protein degrader modality with overlapping oncology pipeline targets.

Regional players

• Rigel Pharmaceuticals: Commercial-stage US biotech that licensed global rights to VEPPANU from Arvinas/Pfizer. Comparable as a smaller US-based oncology/immunology biotech commercializing an Arvinas-originated PROTAC, illustrating Arvinas' partner-dependent go-to-market model.

Emerging players

• Amphista Therapeutics: Emerging targeted protein degradation company developing next-generation 'next-generation' TPD molecules with differentiated E3 ligase recruitment. Comparable to Arvinas at the protein degrader platform level though earlier-stage and pre-clinical.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/arvinasinc
• LinkedInlinkedin.com/company/arvinas
• Facebookfacebook.com/Arvinas-100578376985397

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds5 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arvinas